{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:24:32Z","timestamp":1786991072137,"version":"build-2736575974"},"reference-count":216,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.intimp.2024.112020","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T06:14:24Z","timestamp":1712816064000},"page":"112020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Potential therapeutic options for celiac Disease: An update on Current evidence from Gluten-Free diet to cell therapy"],"prefix":"10.1016","volume":"133","author":[{"given":"Effat","family":"Noori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delsuz","family":"Rezaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Maleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5862-2679","authenticated-orcid":false,"given":"Forough","family":"Shams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Kazemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojgan","family":"Bandepour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fardin","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2024.112020_b0005","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrgastro.2010.23","article-title":"The spectrum of celiac disease: epidemiology, clinical aspects and treatment","volume":"7","author":"Tack","year":"2010","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112020_b0010","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.3390\/ijms24032075","article-title":"Celiac disease genetics, pathogenesis, and standard therapy for japanese patients","volume":"24","author":"Tamai","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.112020_b0015","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00034.2006","article-title":"Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease","author":"Stepniak","year":"2006","journal-title":"Am. J. Phys. Gastrointest. LiverPhysiology"},{"issue":"3","key":"10.1016\/j.intimp.2024.112020_b0020","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bpg.2015.04.005","article-title":"Therapeutic approaches for celiac disease","volume":"29","author":"Plugis","year":"2015","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.intimp.2024.112020_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-019-1380-z","article-title":"Celiac disease: a comprehensive current review","volume":"17","author":"Caio","year":"2019","journal-title":"BMC Med."},{"issue":"7","key":"10.1016\/j.intimp.2024.112020_b0030","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1517\/14728222.2012.688808","article-title":"Future treatment strategies for celiac disease","volume":"16","author":"Lindfors","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"issue":"10","key":"10.1016\/j.intimp.2024.112020_b0035","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.3390\/nu5104250","article-title":"The gluten-free diet: testing alternative cereals tolerated by celiac patients","volume":"5","author":"Comino","year":"2013","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.26719\/2014.20.1.51","article-title":"Prevalence of coeliac disease among adult patients with autoimmune hypothyroidism in Jordan","volume":"20","author":"Farahid","year":"2014","journal-title":"EMHJ-Eastern Mediterranean Health Journal"},{"issue":"6","key":"10.1016\/j.intimp.2024.112020_b0045","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/MPG.0000000000001698","article-title":"New celiac icebergs are spotted, other are slowly emerging","volume":"65","author":"Catassi","year":"2017","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"8","key":"10.1016\/j.intimp.2024.112020_b0050","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3109\/07853890.2010.505931","article-title":"The prevalence of celiac disease in Europe: results of a centralized, international mass screening project","volume":"42","author":"Mustalahti","year":"2010","journal-title":"Ann. Med."},{"key":"10.1016\/j.intimp.2024.112020_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-230X-14-59","article-title":"Celiac disease risk varies between birth cohorts, generating hypotheses about causality: evidence from 36 years of population-based follow-up","volume":"14","author":"Namatovu","year":"2014","journal-title":"BMC Gastroenterol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0060","doi-asserted-by":"crossref","first-page":"30980","DOI":"10.1038\/srep30980","article-title":"Addressing proteolytic efficiency in enzymatic degradation therapy for celiac disease","volume":"6","author":"Rey","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2024.112020_b0065","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fped.2019.00193","article-title":"Evolving therapy for celiac disease","volume":"7","author":"Yoosuf","year":"2019","journal-title":"Front. Pediatr."},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0070","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrgastro.2013.141","article-title":"Advances in the treatment of coeliac disease: an immunopathogenic perspective","volume":"11","author":"Kaukinen","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2024.112020_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/genes14020376","article-title":"Malignancies in patients with celiac disease: Diagnostic challenges and molecular advances","volume":"14","author":"Ivanova","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.intimp.2024.112020_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102268","article-title":"Celiac disease: New therapies on the horizon","volume":"66","author":"Dieckman","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112020_b0085","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.3389\/fimmu.2018.02056","article-title":"The use of human mesenchymal stem cells as therapeutic agents for the in vivo treatment of immune-related diseases: a systematic review","volume":"9","author":"Leyendecker","year":"2018","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112020_b0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.12691\/ijcd-3-4-8","article-title":"The world incidence and prevalence of autoimmune diseases is increasing","volume":"3","author":"Lerner","year":"2015","journal-title":"Int J Celiac Dis"},{"issue":"6","key":"10.1016\/j.intimp.2024.112020_b0095","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.autrev.2015.01.009","article-title":"Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease","volume":"14","author":"Lerner","year":"2015","journal-title":"Autoimmun. Rev."},{"issue":"8","key":"10.1016\/j.intimp.2024.112020_b0100","doi-asserted-by":"crossref","first-page":"14269","DOI":"10.3390\/ijms150814269","article-title":"Expert panel workshop consensus statement on the role of the environment in the development of autoimmune disease","volume":"15","author":"Parks","year":"2014","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.intimp.2024.112020_b0105","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.034520","article-title":"Effect of dietary additives on intestinal permeability in both Drosophila and a human cell co-culture","volume":"11","author":"Pereira","year":"2018","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.intimp.2024.112020_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.718710","article-title":"The influence of nutrition on intestinal permeability and the microbiome in health and disease","volume":"9","author":"Inczefi","year":"2022","journal-title":"Front. Nutr."},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2010.04139.x","article-title":"The \u2018hygiene hypothesis\u2019 for autoimmune and allergic diseases: an update","volume":"160","author":"Okada","year":"2010","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112020_b0120","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jama.2019.10329","article-title":"Association of gluten intake during the first 5 years of life with incidence of celiac disease autoimmunity and celiac disease among children at increased risk","volume":"322","author":"Aronsson","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2024.112020_b0125","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fmed.2014.00006","article-title":"Current and emerging therapy for celiac disease","volume":"1","author":"Makharia","year":"2014","journal-title":"Front. Med."},{"issue":"11","key":"10.1016\/j.intimp.2024.112020_b0130","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1136\/gutjnl-2021-326257","article-title":"Immunopathogenesis and environmental triggers in coeliac disease","volume":"71","author":"Levescot","year":"2022","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.intimp.2024.112020_b0135","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.giec.2012.07.003","article-title":"Pathophysiology of celiac disease","volume":"22","author":"Kupfer","year":"2012","journal-title":"Gastrointest Endosc Clin N Am"},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.immuni.2007.05.015","article-title":"A structural and immunological basis for the role of human leukocyte antigen DQ8 in celiac disease","volume":"27","author":"Henderson","year":"2007","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.intimp.2024.112020_b0145","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1053\/j.gastro.2005.07.030","article-title":"Celiac disease: caught between a rock and a hard place","volume":"129","author":"Koning","year":"2005","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.intimp.2024.112020_b0150","first-page":"582","article-title":"Emerging therapeutic options for celiac disease: potential alternatives to a gluten-free diet","volume":"8","author":"Bakshi","year":"2012","journal-title":"Gastroenterology & Hepatology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1357-2725(03)00239-5","article-title":"The pathogenesis of coeliac disease","volume":"36","author":"Dewar","year":"2004","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112020_b0160","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S2468-1253(22)00428-9","article-title":"Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study","volume":"8","author":"Tye-Din","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112020_b0165","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0753-3322(01)80003-2","article-title":"Histopathology of celiac disease","volume":"54","author":"Oberhuber","year":"2000","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0170","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1309\/AJCPE89ZPVJTSPWL","article-title":"Gastrointestinal pathology in celiac disease: a case series of 150 consecutive newly diagnosed patients","volume":"138","author":"Brown","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112020_b0175","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1038\/ctg.2017.41","article-title":"Clinical and histologic mimickers of celiac disease","volume":"8","author":"Kamboj","year":"2017","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112020_b0180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4291\/wjgp.v8.i2.27","article-title":"Celiac disease: From pathophysiology to treatment","volume":"8","author":"Parzanese","year":"2017","journal-title":"World Journal of Gastrointestinal Pathophysiology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0185","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.giec.2016.08.011","article-title":"Diagnosis and updates in celiac disease","volume":"27","author":"Shannahan","year":"2017","journal-title":"Gastrointestinal Endoscopy Clinics"},{"issue":"2","key":"10.1016\/j.intimp.2024.112020_b0190","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jcmgh.2016.12.006","article-title":"Celiac disease: role of the epithelial barrier","volume":"3","author":"Schumann","year":"2017","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112020_b0195","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/bip.21188","article-title":"Exploring the interactions of gliadins with model membranes: Effect of confined geometry and interfaces","volume":"91","author":"Banc","year":"2009","journal-title":"Biopolymers: Original Research on Biomolecules"},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj2670001","article-title":"The prolamin storage proteins of cereal seeds: structure and evolution","volume":"267","author":"Shewry","year":"1990","journal-title":"Biochem. J"},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0205","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/aob\/mcr098","article-title":"Distribution of gluten proteins in bread wheat (Triticum aestivum) grain","volume":"108","author":"Tosi","year":"2011","journal-title":"Ann. Bot."},{"issue":"2","key":"10.1016\/j.intimp.2024.112020_b0210","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.fm.2006.07.004","article-title":"Chemistry of gluten proteins","volume":"24","author":"Wieser","year":"2007","journal-title":"Food Microbiol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0215","first-page":"12","article-title":"Non-dietary methods in the treatment of celiac disease","volume":"10","author":"Szaflarska-Pop\u0142awska","year":"2015","journal-title":"Gastroenterology Review\/przegl\u0105d Gastroenterologiczny"},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0220","article-title":"Gluten in celiac disease\u2014more or less?","volume":"10","author":"Cohen","year":"2019","journal-title":"Rambam Maimonides Medical Journal"},{"issue":"11","key":"10.1016\/j.intimp.2024.112020_b0225","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.3390\/nu11112587","article-title":"Gliadin intake causes disruption of the intestinal barrier and an increase in germ cell apoptosis in a Caenorhabditis elegans model","volume":"11","author":"Min","year":"2019","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.intimp.2024.112020_b0230","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1080\/00365520500235334","article-title":"Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines","volume":"41","author":"Drago","year":"2006","journal-title":"Scand. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112020_b0235","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2337\/ds16-0022","article-title":"The gluten-free diet: fad or necessity?","volume":"30","author":"Jones","year":"2017","journal-title":"Diabetes Spectrum"},{"issue":"5","key":"10.1016\/j.intimp.2024.112020_b0240","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2036.2006.02768.x","article-title":"Safe amounts of gluten for patients with wheat allergy or coeliac disease","volume":"23","author":"Hischenhuber","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.intimp.2024.112020_b0245","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/j.1365-2036.2008.03669.x","article-title":"Systematic review: tolerable amount of gluten for people with coeliac disease","volume":"27","author":"Akobeng","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.intimp.2024.112020_b0250","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/01.meg.0000236884.21343.e4","article-title":"Consumption of gluten-free products: should the threshold value for trace amounts of gluten be at 20, 100 or 200 ppm?","volume":"18","author":"Gibert","year":"2006","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112020_b0255","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1586\/17474124.2015.1033399","article-title":"Celiac disease 2015 update: new therapies","volume":"9","author":"Veeraraghavan","year":"2015","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112020_b0260","doi-asserted-by":"crossref","first-page":"8733","DOI":"10.3390\/nu7105426","article-title":"The spectrum of differences between childhood and adulthood celiac disease","volume":"7","author":"Ciccocioppo","year":"2015","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/j.intimp.2024.112020_b0265","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ncpgasthep0212","article-title":"Is a life-long gluten-free diet for patients with celiac disease successful?","volume":"2","author":"Ciccocioppo","year":"2005","journal-title":"Nat. Clin. Pract. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112020_b0270","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/jcag\/gwy067","article-title":"The gluten free diet: Assessing adherence in a pediatric celiac disease population","volume":"3","author":"Dowhaniuk","year":"2020","journal-title":"Journal of the Canadian Association of Gastroenterology"},{"issue":"7","key":"10.1016\/j.intimp.2024.112020_b0275","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.3390\/nu13072274","article-title":"Challenges of monitoring the gluten-free diet adherence in the management and follow-up of patients with celiac disease","volume":"13","author":"Wieser","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.intimp.2024.112020_b0280","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.tifs.2018.12.005","article-title":"Factors affecting consumers' adherence to gluten-free diet, a systematic review","volume":"85","author":"Xhakollari","year":"2019","journal-title":"Trends Food Sci. Technol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112020_b0285","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/08830185.2011.602443","article-title":"New clues in celiac disease epidemiology, pathogenesis, clinical manifestations, and treatment","volume":"30","author":"Lionetti","year":"2011","journal-title":"Int. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112020_b0290","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1365-2036.1996.66237000.x","article-title":"Management of patients with non-responsive coeliac disease","volume":"10","author":"O'mahony","year":"1996","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0295","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/nu12010216","article-title":"Non-responsive coeliac disease: a comprehensive review from the NHS england national centre for refractory coeliac disease","volume":"12","author":"Penny","year":"2020","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0300","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/MPG.0000000000001634","article-title":"Celiac disease symptom resolution: effectiveness of the gluten-free diet","volume":"66","author":"Sansotta","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"10","key":"10.1016\/j.intimp.2024.112020_b0305","doi-asserted-by":"crossref","first-page":"8733","DOI":"10.3390\/nu7105426","article-title":"The spectrum of differences between childhood and adulthood celiac disease","volume":"7","author":"Ciccocioppo","year":"2015","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.intimp.2024.112020_b0310","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1128\/CMR.00106-13","article-title":"Intestinal microbiota and probiotics in celiac disease","volume":"27","author":"de Sousa Moraes","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2024.112020_b0315","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/ncpgasthep0111","article-title":"Future therapeutic options for celiac disease","volume":"2","author":"Sollid","year":"2005","journal-title":"Nat. Clin. Pract. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112020_b0320","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.chembiol.2006.04.009","article-title":"Rational design of combination enzyme therapy for celiac sprue","volume":"13","author":"Siegel","year":"2006","journal-title":"Chem. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112020_b0325","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1053\/j.gastro.2007.05.028","article-title":"Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue","volume":"133","author":"Gass","year":"2007","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.intimp.2024.112020_b0330","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1124\/jpet.106.104315","article-title":"Effect of barley endoprotease EP-B2 on gluten digestion in the intact rat","volume":"318","author":"Gass","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2024.112020_b0335","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.clim.2009.11.001","article-title":"The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo","volume":"134","author":"Tye-Din","year":"2010","journal-title":"Clin. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112020_b0340","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.molmet.2017.05.008","article-title":"The human digestive tract has proteases capable of gluten hydrolysis","volume":"6","author":"Guti\u00e9rrez","year":"2017","journal-title":"Molecular Metabolism"},{"issue":"6","key":"10.1016\/j.intimp.2024.112020_b0345","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.chembiol.2006.04.008","article-title":"Heterologous expression, purification, refolding, and structural-functional characterization of EP-B2, a self-activating barley cysteine endoprotease","volume":"13","author":"Bethune","year":"2006","journal-title":"Chem. Biol."},{"issue":"40","key":"10.1016\/j.intimp.2024.112020_b0350","doi-asserted-by":"crossref","first-page":"13106","DOI":"10.1021\/jacs.5b08325","article-title":"Engineering of Kuma030: a gliadin peptidase that rapidly degrades immunogenic gliadin peptides in gastric conditions","volume":"137","author":"Wolf","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.intimp.2024.112020_b0355","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320904301","article-title":"Assessing the association between dipeptidyl peptidase-4 inhibitors use and celiac disease through drug adverse event reporting","volume":"11","author":"Li","year":"2020","journal-title":"Therapeutic Advances in Chronic Disease"},{"issue":"7","key":"10.1016\/j.intimp.2024.112020_b0360","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3390\/ijms18071395","article-title":"Rational design of recombinant papain-like cysteine protease: Optimal domain structure and expression conditions for wheat-derived enzyme triticain-\u03b1","volume":"18","author":"Gorokhovets","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2024.112020_b0365","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.3390\/nu12072095","article-title":"Gluten degrading enzymes for treatment of celiac disease","volume":"12","author":"Wei","year":"2020","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0370","doi-asserted-by":"crossref","first-page":"13100","DOI":"10.1038\/s41598-017-13587-7","article-title":"Randomized clinical trial: Effective gluten degradation by Aspergillus niger-derived enzyme in a complex meal setting","volume":"7","author":"K\u00f6nig","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2024.112020_b0375","first-page":"E68","article-title":"Food-grade gluten degrading enzymes to treat dietary transgressions in coeliac adolescents","volume":"50","author":"Korponay-Szabo","year":"2010","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"7","key":"10.1016\/j.intimp.2024.112020_b0380","doi-asserted-by":"crossref","first-page":"e6313","DOI":"10.1371\/journal.pone.0006313","article-title":"A food-grade enzyme preparation with modest gluten detoxification properties","volume":"4","author":"Ehren","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2024.112020_b0385","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.974771","article-title":"E40 glutenase detoxification capabilities of residual gluten immunogenic peptides in in vitro gastrointestinal digesta of food matrices made of soft and durum wheat","volume":"9","author":"Mamone","year":"2022","journal-title":"Front. Nutr."},{"key":"10.1016\/j.intimp.2024.112020_b0390","unstructured":"AG, A.B., AMYRA Biotech\u2014Solutions for gluten-related disorders."},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0395","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.bbadis.2005.09.008","article-title":"VSL# 3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for celiac sprue probiotics and gluten intolerance","volume":"1762","author":"De Angelis","year":"2006","journal-title":"Biochimica Et Biophysica Acta (BBA)-Molecular Basis of Disease"},{"issue":"6","key":"10.1016\/j.intimp.2024.112020_b0400","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3920\/BM2020.0016","article-title":"Effect of Bifidobacterium infantis NLS super strain in symptomatic coeliac disease patients on long-term gluten-free diet\u2013an exploratory study","volume":"11","author":"Smecuol","year":"2020","journal-title":"Benefic. Microbes"},{"issue":"3","key":"10.1016\/j.intimp.2024.112020_b0405","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1097\/MCG.0000000000001023","article-title":"Clinical and microbiological effect of a multispecies probiotic supplementation in celiac patients with persistent IBS-type symptoms: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"53","author":"Francavilla","year":"2019","journal-title":"J. Clin. Gastroenterol."},{"issue":"11","key":"10.1016\/j.intimp.2024.112020_b0410","doi-asserted-by":"crossref","first-page":"e109972","DOI":"10.1371\/journal.pone.0109972","article-title":"BL-7010 demonstrates specific binding to gliadin and reduces gluten-associated pathology in a chronic mouse model of gliadin sensitivity","volume":"9","author":"McCarville","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2024.112020_b0415","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s10620-016-4426-5","article-title":"AGY, a novel egg yolk-derived anti-gliadin antibody, is safe for patients with celiac disease","volume":"62","author":"Sample","year":"2017","journal-title":"Dig. Dis. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2024.112020_b0420","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/ajg.2014.48","article-title":"Novel role of the serine protease inhibitor elafin in gluten-related disorders","volume":"109","author":"Galipeau","year":"2014","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101782","article-title":"Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials","volume":"46","author":"Hoilat","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112020_b0430","first-page":"476","article-title":"Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia","volume":"121","author":"Waldmann","year":"2013","journal-title":"Blood, the Journal of the American Society of Hematology"},{"issue":"3","key":"10.1016\/j.intimp.2024.112020_b0435","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/j.gastro.2019.10.006","article-title":"Identification of a \u03b3c receptor antagonist that prevents reprogramming of human tissue-resident cytotoxic T cells by IL15 and IL21","volume":"158","author":"Ciszewski","year":"2020","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.intimp.2024.112020_b0440","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S2468-1253(19)30264-X","article-title":"Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study","volume":"4","author":"L\u00e4hdeaho","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2024.112020_b0445","series-title":"Mabs","article-title":"Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis","author":"Vicari","year":"2017"},{"issue":"4","key":"10.1016\/j.intimp.2024.112020_b0450","doi-asserted-by":"crossref","first-page":"e244692","DOI":"10.1136\/bcr-2021-244692","article-title":"Successful novel use of tofacitinib for type II refractory coeliac disease","volume":"15","author":"Grewal","year":"2022","journal-title":"BMJ Case Reports CP"},{"key":"10.1016\/j.intimp.2024.112020_b0455","unstructured":"Avaxia Biologics. Avaxia Biologics is Awarded Patent for its Proprietary Orally Active Antibody for Celiac Disease. Internet, 2011[cited 2014 Nov 23]. Available from: http:\/\/www.avaxiabiologics.com\/docs\/rev-11-12-13-Celiac-Disease-Treatment-Patent.pdf."},{"issue":"2","key":"10.1016\/j.intimp.2024.112020_b0460","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/gastro\/gov006","article-title":"Development of drugs for celiac disease: review of endpoints for Phase 2 and 3 trials","volume":"3","author":"Gottlieb","year":"2015","journal-title":"Gastroenterology Report"},{"issue":"1_Supplement","key":"10.1016\/j.intimp.2024.112020_b0465","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.210.Supp.243.19","article-title":"\u03b3c receptor antagonist, EQ102, prevents the NK and T cell-mediated responses driven by IL-15 and IL-21","volume":"210","author":"Tiet","year":"2023","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0470","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1038\/s41467-023-44083-4","article-title":"Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide: HLA-DQ2. 5 complexes in the context of celiac disease","volume":"14","author":"Okura","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0475","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","article-title":"Natalizumab for active Crohn's disease","volume":"348","author":"Ghosh","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0480","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1124\/jpet.110.169714","article-title":"Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease","volume":"335","author":"Walters","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.intimp.2024.112020_b0485","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3389\/fimmu.2017.00806","article-title":"Pharmacodynamic monitoring of RO5459072, a small molecule inhibitor of cathepsin S","volume":"8","author":"Theron","year":"2017","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112020_b0490","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.immuni.2004.06.018","article-title":"A direct role for NKG2D\/MICA interaction in villous atrophy during celiac disease","volume":"21","author":"H\u00fce","year":"2004","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.intimp.2024.112020_b0495","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.bmc.2007.10.091","article-title":"Design of azidoproline containing gluten peptides to suppress CD4+ T-cell responses associated with celiac disease","volume":"16","author":"Kapoerchan","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"10.1016\/j.intimp.2024.112020_b0500","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jcmgh.2019.04.017","article-title":"Novel nondietary therapies for celiac disease","volume":"8","author":"Alhassan","year":"2019","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2024.112020_b0505","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaut.2007.11.007","article-title":"In vitro induction of regulatory T cells by anti-CD3 antibody in humans","volume":"30","author":"Abraham","year":"2008","journal-title":"J. Autoimmun."},{"issue":"24","key":"10.1016\/j.intimp.2024.112020_b0510","first-page":"5181","article-title":"Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab","volume":"116","author":"Mei","year":"2010","journal-title":"Blood, the Journal of the American Society of Hematology"},{"issue":"3","key":"10.1016\/j.intimp.2024.112020_b0515","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1053\/gast.2002.31874","article-title":"Successful infliximab treatment for steroid-refractory celiac disease: a case report","volume":"122","author":"Gillett","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.112020_b0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103506","article-title":"Gastrointestinal pathologic findings of teriflunomide associated diarrhea","volume":"58","author":"Fan","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"Supplement_1","key":"10.1016\/j.intimp.2024.112020_b0525","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1093\/ibd\/izac247.024","article-title":"A novel bispecific CD8 Treg modulator targeting cytolytic CD8 regulatory T cells reduces pathogenic CD4 T cells and inflammation in translational models of intestinal autoimmune and inflammatory disease","volume":"29","author":"Gardell","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"issue":"3\u20134","key":"10.1016\/j.intimp.2024.112020_b0530","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijpara.2012.12.005","article-title":"Changed gluten immunity in celiac disease by Necator americanus provides new insights into autoimmunity","volume":"43","author":"Croese","year":"2013","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.intimp.2024.112020_b0535","series-title":"Gluten-related disorders","first-page":"149","article-title":"Treatment of gluten-related disorders","author":"Yoosuf","year":"2022"},{"issue":"5","key":"10.1016\/j.intimp.2024.112020_b0540","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1053\/j.gastro.2005.07.054","article-title":"Unexpected role of surface transglutaminase type II in celiac disease","volume":"129","author":"Maiuri","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.112020_b0545","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s10875-012-9745-5","article-title":"Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study","volume":"33","author":"Rauhavirta","year":"2013","journal-title":"J. Clin. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112020_b0550","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.3390\/cells11101667","article-title":"Features of ZED1227: The first-in-class tissue transglutaminase inhibitor undergoing clinical evaluation for the treatment of celiac disease","volume":"11","author":"B\u00fcchold","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2024.112020_b0555","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s11095-012-0951-x","article-title":"Celiac disease: a challenging disease for pharmaceutical scientists","volume":"30","author":"Matoori","year":"2013","journal-title":"Pharm. Res."},{"issue":"18","key":"10.1016\/j.intimp.2024.112020_b0560","first-page":"31861","article-title":"The oral transglutaminase 2 (TG2) inhibitor Zed1227 blocks TG2 activity in a mouse model of intestinal inflammation","volume":"154","author":"Ventura","year":"2018","journal-title":"Gastroenterology"},{"issue":"13","key":"10.1016\/j.intimp.2024.112020_b0565","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1073\/pnas.0832466100","article-title":"Transglutaminase 2-\/-mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells","volume":"100","author":"Szondy","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"24","key":"10.1016\/j.intimp.2024.112020_b0570","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1021\/acs.biochem.8b00204","article-title":"Cystamine and disulfiram inhibit human transglutaminase 2 via an oxidative mechanism","volume":"57","author":"Palanski","year":"2018","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/j.intimp.2024.112020_b0575","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180691","article-title":"Cystamine and cysteamine as inhibitors of transglutaminase activity in vivo","volume":"38","author":"Jeitner","year":"2018","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.intimp.2024.112020_b0580","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.623805","article-title":"Celiac disease causes epithelial disruption and regulatory T cell recruitment in the oral mucosa","volume":"12","author":"Sanchez-Solares","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0585","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.gastro.2021.03.014","article-title":"TAK-101 nanoparticles induce gluten-specific tolerance in celiac disease: a randomized, double-blind, placebo-controlled study","volume":"161","author":"Kelly","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0590","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.gastro.2021.03.019","article-title":"Gluten degradation, pharmacokinetics, safety, and tolerability of TAK-062, an engineered enzyme to treat celiac disease","volume":"161","author":"Pultz","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0595","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1038\/s41598-019-43837-9","article-title":"Pharmaceutically modified subtilisins withstand acidic conditions and effectively degrade gluten in vivo","volume":"9","author":"Darwish","year":"2019","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.intimp.2024.112020_b0600","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1053\/j.gastro.2020.01.045","article-title":"Gliadin nanoparticles induce immune tolerance to gliadin in mouse models of celiac disease","volume":"158","author":"Freitag","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.112020_b0605","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fnut.2020.00152","article-title":"Celiac disease and non-celiac wheat sensitivity: state of art of non-dietary therapies","volume":"7","author":"Serena","year":"2020","journal-title":"Front. Nutr."},{"key":"10.1016\/j.intimp.2024.112020_b0610","unstructured":"Kelly CP, M.J., Leffler D, Bledsoe A, Smithson G, Podojil JR et al., CNP-101 prevents gluten challenge induced immune activation in adults with celiac disease. United European Gastroenterology Week, 2019 10\/22\/2019. Barcelona, Spain."},{"key":"10.1016\/j.intimp.2024.112020_b0615","article-title":"A study to assess the safety of TPM502 in","author":"GmbH","year":"2023","journal-title":"Adults with Celiac Disease."},{"key":"10.1016\/j.intimp.2024.112020_b0620","article-title":"Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial","author":"Murray","year":"2023","journal-title":"LancetGastroenterology & Hepatology"},{"issue":"16","key":"10.1016\/j.intimp.2024.112020_b0625","doi-asserted-by":"crossref","first-page":"12800","DOI":"10.3390\/ijms241612800","article-title":"Old and new adjunctive therapies in celiac disease and refractory celiac disease: A review","volume":"24","author":"Valvano","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl1","key":"10.1016\/j.intimp.2024.112020_b0630","first-page":"S1","article-title":"Mesenchymal stem cells as potential therapeutic approaches in celiac disease","volume":"9","author":"Moheb-Alian","year":"2016","journal-title":"Gastroenterology and Hepatology from Bed to Bench"},{"issue":"2","key":"10.1016\/j.intimp.2024.112020_b0635","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4252\/wjsc.v6.i2.213","article-title":"Intestinal stem cells and celiac disease","volume":"6","author":"Piscaglia","year":"2014","journal-title":"World Journal of Stem Cells"},{"key":"10.1016\/j.intimp.2024.112020_b0640","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-015-0591-0","article-title":"Circulating hematopoietic stem cells and putative intestinal stem cells in coeliac disease","volume":"13","author":"Piscaglia","year":"2015","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.intimp.2024.112020_b0645","doi-asserted-by":"crossref","first-page":"S-1204","DOI":"10.1016\/S0016-5085(23)03781-2","article-title":"EP63 First in human trial of IMU-856, an orally available regulator of barrier function for the treatment of celiac disease","volume":"164","author":"Buri\u00e1nek","year":"2023","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.intimp.2024.112020_b0650","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/pbi.12455","article-title":"Targeting of prolamins by RNA i in bread wheat: effectiveness of seven silencing-fragment combinations for obtaining lines devoid of coeliac disease epitopes from highly immunogenic gliadins","volume":"14","author":"Barro","year":"2016","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.intimp.2024.112020_b0655","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fnut.2020.00051","article-title":"CRISPR\/Cas9 gene editing of gluten in wheat to reduce gluten content and exposure-reviewing methods to screen for coeliac safety","volume":"7","author":"Jouanin","year":"2020","journal-title":"Front Nutr"},{"issue":"10","key":"10.1016\/j.intimp.2024.112020_b0660","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3390\/foods10102351","article-title":"Current status and perspectives on the application of CRISPR\/Cas9 gene-editing system to develop a low-gluten, non-transgenic wheat variety","volume":"10","author":"Verma","year":"2021","journal-title":"Foods"},{"key":"10.1016\/j.intimp.2024.112020_b0665","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.tifs.2018.02.021","article-title":"Next-generation therapies for celiac disease: The gluten-targeted approaches","volume":"75","author":"Ribeiro","year":"2018","journal-title":"Trends Food Sci. Technol."},{"key":"10.1016\/j.intimp.2024.112020_b0670","series-title":"Springer seminars in immunopathology","article-title":"Gluten: a two-edged sword. immunopathogenesis of celiac disease","author":"Koning","year":"2005"},{"issue":"41","key":"10.1016\/j.intimp.2024.112020_b0675","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001012","article-title":"Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease","volume":"2","author":"Tye-Din","year":"2010","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.112020_b0680","doi-asserted-by":"crossref","first-page":"G996","DOI":"10.1152\/ajpgi.00136.2002","article-title":"Intestinal digestive resistance of immunodominant gliadin peptides","volume":"283","author":"Hausch","year":"2002","journal-title":"Am. J. Phys. Gastrointest. LiverPhysiology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0685","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1146\/annurev.immunol.18.1.53","article-title":"Molecular basis of celiac disease","volume":"18","author":"Sollid","year":"2000","journal-title":"Annu. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112020_b0690","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2036.2012.05013.x","article-title":"coeliac disease, new approaches to therapy","volume":"35","author":"Rashtak","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2024.112020_b0695","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00251-012-0599-z","article-title":"Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by HLA-DQ molecules","volume":"64","author":"Sollid","year":"2012","journal-title":"Immunogenetics"},{"key":"10.1016\/j.intimp.2024.112020_b0700","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.fct.2019.05.011","article-title":"Prolyl endopeptidase-degraded low immunoreactive wheat flour attenuates immune responses in Caco-2 intestinal cells and gluten-sensitized BALB\/c mice","volume":"129","author":"Mohan Kumar","year":"2019","journal-title":"Food Chem. Toxicol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112020_b0705","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3748\/wjg.v7.i6.772","article-title":"Pathogenesis of coeliac disease: implications for treatment","volume":"7","author":"Fraser","year":"2001","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.intimp.2024.112020_b0710","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00018-006-6317-y","article-title":"Prolyl endopeptidases","volume":"64","author":"Gass","year":"2007","journal-title":"Cell. Mol. Life Sci."},{"issue":"10","key":"10.1016\/j.intimp.2024.112020_b0715","doi-asserted-by":"crossref","first-page":"e13264","DOI":"10.1371\/journal.pone.0013264","article-title":"Discovery of a novel and rich source of gluten-degrading microbial enzymes in the oral cavity","volume":"5","author":"Helmerhorst","year":"2010","journal-title":"PLoS One"},{"issue":"5590","key":"10.1016\/j.intimp.2024.112020_b0720","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1126\/science.1074129","article-title":"Structural basis for gluten intolerance in celiac sprue","volume":"297","author":"Shan","year":"2002","journal-title":"Science"},{"issue":"Pt 2","key":"10.1016\/j.intimp.2024.112020_b0725","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1042\/BJ20040907","article-title":"Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue","volume":"383","author":"Shan","year":"2004","journal-title":"Biochem J"},{"issue":"7","key":"10.1016\/j.intimp.2024.112020_b0730","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1542-3565(05)00366-6","article-title":"Effect of pretreatment of food gluten with prolyl endopeptidase on gluten-induced malabsorption in celiac sprue","volume":"3","author":"Pyle","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112020_b0735","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/apt.13266","article-title":"Randomised clinical study: Aspergillus niger-derived enzyme digests gluten in the stomach of healthy volunteers","volume":"42","author":"Salden","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2024.112020_b0740","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fnut.2020.00011","article-title":"Directed-mutagenesis of Flavobacterium meningosepticum prolyl-oligopeptidase and a glutamine-specific endopeptidase from barley","volume":"7","author":"Osorio","year":"2020","journal-title":"Front. Nutr."},{"key":"10.1016\/j.intimp.2024.112020_b0745","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coph.2015.09.002","article-title":"Pharmacological approaches in celiac disease","volume":"25","author":"McCarville","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112020_b0750","first-page":"1437","article-title":"Study of wheat protein degradation during germination","volume":"1","author":"Michalcov\u00e1","year":"2012","journal-title":"The Journal of Microbiology, Biotechnology and Food Sciences"},{"key":"10.1016\/j.intimp.2024.112020_b0755","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s10620-011-1906-5","article-title":"Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials","volume":"57","author":"Siegel","year":"2012","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.intimp.2024.112020_b0760","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.foodres.2016.11.021","article-title":"Novel approaches for enzymatic gluten degradation to create high-quality gluten-free products","volume":"110","author":"Scherf","year":"2018","journal-title":"Food Res. Int."},{"issue":"12","key":"10.1016\/j.intimp.2024.112020_b0765","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.3390\/nu10121824","article-title":"Probiotics in celiac disease","volume":"10","author":"Cristofori","year":"2018","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.intimp.2024.112020_b0770","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2249.2008.03635.x","article-title":"Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture","volume":"152","author":"Lindfors","year":"2008","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112020_b0775","doi-asserted-by":"crossref","first-page":"e30744","DOI":"10.1371\/journal.pone.0030744","article-title":"Bifidobacterium longum CECT 7347 modulates immune responses in a gliadin-induced enteropathy animal model","volume":"7","author":"Laparra","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.intimp.2024.112020_b0780","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/ibd.20525","article-title":"Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases","volume":"14","author":"Vanderpool","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"issue":"2","key":"10.1016\/j.intimp.2024.112020_b0785","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1053\/j.gastro.2011.10.038","article-title":"The copolymer P (HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues","volume":"142","author":"Pinier","year":"2012","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.intimp.2024.112020_b0790","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/ajg.2012.211","article-title":"A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge","volume":"107","author":"Leffler","year":"2012","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112020_b0795","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/apt.12147","article-title":"Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study","volume":"37","author":"Kelly","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2024.112020_b0800","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/ani12020145","article-title":"Integrity of the intestinal barrier: The involvement of epithelial cells and microbiota\u2014A mutual relationship","volume":"12","author":"Giery\u0144ska","year":"2022","journal-title":"Animals"},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0805","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jcmgh.2020.07.004","article-title":"Regulation of intestinal epithelial barrier and immune function by activated T cells","volume":"11","author":"Le","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0810","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1749-6632.2012.06538.x","article-title":"Zonulin, regulation of tight junctions, and autoimmune diseases","volume":"1258","author":"Fasano","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2024.112020_b0815","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/gutjnl-2011-300327","article-title":"Intestinal permeability in coeliac disease: insight into mechanisms and relevance to pathogenesis","volume":"61","author":"Heyman","year":"2012","journal-title":"Gut"},{"issue":"9214","key":"10.1016\/j.intimp.2024.112020_b0820","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(00)02169-3","article-title":"Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease","volume":"355","author":"Fasano","year":"2000","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.intimp.2024.112020_b0825","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/MPG.0000000000000338","article-title":"Alteration of tight junction gene expression in celiac disease","volume":"58","author":"Jauregi-Miguel","year":"2014","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0830","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2249.2010.04317.x","article-title":"Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A","volume":"164","author":"Rauhavirta","year":"2011","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112020_b0835","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.4049\/jimmunol.180.3.1800","article-title":"Autocrine regulation of IL-21 production in human T lymphocytes","volume":"180","author":"Caprioli","year":"2008","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112020_b0840","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/mi.2012.65","article-title":"IL-15 positively regulates IL-21 production in celiac disease mucosa","volume":"6","author":"Sarra","year":"2013","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.intimp.2024.112020_b0845","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s10875-012-9849-y","article-title":"Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease","volume":"33","author":"Yokoyama","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.intimp.2024.112020_b0850","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3389\/fimmu.2018.01603","article-title":"Beneficial effects of human anti-interleukin-15 antibody in gluten-sensitive rhesus macaques with celiac disease","volume":"9","author":"Sestak","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0855","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/imr.12191","article-title":"IL-15: a central regulator of celiac disease immunopathology","volume":"260","author":"Abadie","year":"2014","journal-title":"Immunol. Rev."},{"issue":"5","key":"10.1016\/j.intimp.2024.112020_b0860","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.molimm.2009.10.036","article-title":"Design, synthesis and evaluation of high-affinity binders for the celiac disease associated HLA-DQ2 molecule","volume":"47","author":"Kapoerchan","year":"2010","journal-title":"Mol. Immunol."},{"issue":"20","key":"10.1016\/j.intimp.2024.112020_b0865","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1016\/j.bmc.2007.07.001","article-title":"Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease","volume":"15","author":"Xia","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.intimp.2024.112020_b0870","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.681062","article-title":"Strategies to use nanoparticles to generate CD4 and CD8 regulatory T cells for the treatment of SLE and other autoimmune diseases","volume":"12","author":"Horwitz","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112020_b0875","article-title":"Nanoparticle-based drug delivery systems for induction of tolerance and treatment of autoimmune diseases","volume":"10","author":"Li","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112020_b0880","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/14728222.2014.985207","article-title":"Transglutaminase as a therapeutic target for celiac disease","volume":"19","author":"Sulic","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b0885","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clim.2015.02.003","article-title":"Nanoparticle-based autoimmune disease therapy","volume":"160","author":"Serra","year":"2015","journal-title":"Clin. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112020_b0890","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.4049\/jimmunol.0901919","article-title":"Characterization of IL-17A-producing cells in celiac disease mucosa","volume":"184","author":"Monteleone","year":"2010","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.intimp.2024.112020_b0895","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/labinvest.3700225","article-title":"Matrix metalloproteinase pattern in celiac duodenal mucosa","volume":"85","author":"Ciccocioppo","year":"2005","journal-title":"Lab Invest"},{"issue":"6","key":"10.1016\/j.intimp.2024.112020_b0900","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0002-9440(10)64319-2","article-title":"Constitutive activation of the signal transducer and activator of transcription pathway in celiac disease lesions","volume":"162","author":"Mazzarella","year":"2003","journal-title":"Am J Pathol"},{"issue":"24","key":"10.1016\/j.intimp.2024.112020_b0905","doi-asserted-by":"crossref","first-page":"7349","DOI":"10.3748\/wjg.v21.i24.7349","article-title":"Effector and suppressor T cells in celiac disease","volume":"21","author":"Mazzarella","year":"2015","journal-title":"World J Gastroenterol: WJG"},{"issue":"12","key":"10.1016\/j.intimp.2024.112020_b0910","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/pro.2162","article-title":"Regulation of the activities of the mammalian transglutaminase family of enzymes","volume":"21","author":"Kl\u00f6ck","year":"2012","journal-title":"Protein Sci."},{"issue":"4","key":"10.1016\/j.intimp.2024.112020_b0915","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1136\/gut.2005.069385","article-title":"Cross linking to tissue transglutaminase and collagen favours gliadin toxicity in coeliac disease","volume":"55","author":"Dieterich","year":"2006","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.intimp.2024.112020_b0920","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1582-4934.2008.00325.x","article-title":"Mucosal tissue transglutaminase expression in celiac disease","volume":"13","author":"Villanacci","year":"2009","journal-title":"J. Cell Mol. Med."},{"issue":"8","key":"10.1016\/j.intimp.2024.112020_b0925","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1074\/jbc.RA117.001382","article-title":"Endoplasmic reticulum\u2013resident protein 57 (ERp57) oxidatively inactivates human transglutaminase 2","volume":"293","author":"Michael","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.intimp.2024.112020_b0930","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.pharmthera.2007.05.003","article-title":"Transglutaminase 2 inhibitors and their therapeutic role in disease states","volume":"115","author":"Siegel","year":"2007","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2024.112020_b0935","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/1521-4141(200105)31:5<1317::AID-IMMU1317>3.0.CO;2-I","article-title":"T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase","volume":"31","author":"Molberg","year":"2001","journal-title":"Eur. J. Immunol."},{"issue":"20","key":"10.1016\/j.intimp.2024.112020_b0940","doi-asserted-by":"crossref","first-page":"5559","DOI":"10.1016\/j.bmcl.2008.09.006","article-title":"Synthesis of potent water-soluble tissue transglutaminase inhibitors","volume":"18","author":"Griffin","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.intimp.2024.112020_b0945","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/apt.15435","article-title":"Randomised clinical trial: a placebo-controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease","volume":"50","author":"Truitt","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.intimp.2024.112020_b0950","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S2468-1253(17)30110-3","article-title":"Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies","volume":"2","author":"Goel","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2024.112020_b0955","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.actatropica.2018.08.032","article-title":"The hygiene hypothesis at a glance: Early exposures, immune mechanism and novel therapies","volume":"188","author":"Alexandre-Silva","year":"2018","journal-title":"Acta Trop."},{"issue":"4","key":"10.1016\/j.intimp.2024.112020_b0960","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.4049\/jimmunol.0802891","article-title":"Induction of antigen-specific tolerance by oral administration of Lactococcus lactis delivered immunodominant DQ8-restricted gliadin peptide in sensitized nonobese diabetic Abo Dq8 transgenic mice","volume":"183","author":"Huibregtse","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2024.112020_b0965","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.3389\/fimmu.2017.01961","article-title":"Lactococcus lactis as a versatile vehicle for tolerogenic immunotherapy","volume":"8","author":"Cook","year":"2018","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112020_b0970","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/ajg.2011.397","article-title":"Impaired control of effector T cells by regulatory T cells: a clue to loss of oral tolerance and autoimmunity in celiac disease?","volume":"107","author":"Hmida","year":"2012","journal-title":"Official Journal of the American College of Gastroenterology| ACG"},{"issue":"12","key":"10.1016\/j.intimp.2024.112020_b0975","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000274","article-title":"Randomized, placebo controlled trial of experimental hookworm infection for improving gluten tolerance in celiac disease","volume":"11","author":"Croese","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112020_b0980","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.it.2019.08.003","article-title":"rebalancing immune homeostasis to treat autoimmune diseases","volume":"40","author":"Horwitz","year":"2019","journal-title":"Trends Immunol"},{"issue":"10","key":"10.1016\/j.intimp.2024.112020_b0985","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.molmed.2019.05.009","article-title":"Therapeutic and diagnostic implications of T cell scarring in celiac disease and beyond","volume":"25","author":"Christophersen","year":"2019","journal-title":"Trends Mol Med"},{"issue":"219","key":"10.1016\/j.intimp.2024.112020_b0990","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007563","article-title":"Therapeutic inflammatory monocyte modulation using immune-modifying microparticles","volume":"6","author":"Getts","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2024.112020_b0995","first-page":"2148","article-title":"Targeted immunomodulation using protein coated nanoparticles","volume":"8","author":"McCarthy","year":"2014","journal-title":"WIRES Nanomed Nanobiotechnol"},{"issue":"5","key":"10.1016\/j.intimp.2024.112020_b1000","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2006-08-042820","article-title":"Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells","volume":"109","author":"Al-toma","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2024.112020_b1005","series-title":"Mayo Clinic Proceedings","article-title":"A refractory celiac patient successfully treated with mesenchymal stem cell infusions","author":"Ciccocioppo","year":"2016"},{"issue":"9","key":"10.1016\/j.intimp.2024.112020_b1010","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1089\/hum.2010.115","article-title":"Bone marrow mesenchymal stem cells: historical overview and concepts","volume":"21","author":"Charbord","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.intimp.2024.112020_b1015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s40472-019-00238-1","article-title":"Mesenchymal stem cells to treat digestive system disorders: Progress made and future directions","volume":"6","author":"Romano","year":"2019","journal-title":"Current Transplantation Reports"},{"issue":"9S","key":"10.1016\/j.intimp.2024.112020_b1020","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1097\/TP.0b013e3181a285b0","article-title":"The immunosuppressive properties of mesenchymal stem cells","volume":"87","author":"Siegel","year":"2009","journal-title":"Transplantation"},{"issue":"9624","key":"10.1016\/j.intimp.2024.112020_b1025","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study","volume":"371","author":"Le Blanc","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2024.112020_b1030","series-title":"Mayo clinic proceedings","article-title":"Mesenchymal stromal cell infusions as rescue therapy for corticosteroid-refractory adult autoimmune enteropathy","author":"Ciccocioppo","year":"2012"},{"issue":"2","key":"10.1016\/j.intimp.2024.112020_b1035","first-page":"1","article-title":"Allogeneic telomerase-positive stem cells as a treatment for celiac disease","volume":"4","author":"Young","year":"2020","journal-title":"Stem Cells Regen Med."},{"key":"10.1016\/j.intimp.2024.112020_b1040","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10620-018-5364-1","article-title":"Autoimmune enteropathy: an updated review with special focus on stem cell transplant therapy","volume":"64","author":"Ahmed","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.intimp.2024.112020_b1045","series-title":"Tissue Regeneration: Where Nano-Structure Meets Biology","first-page":"1","article-title":"Chapter 1: Adult stem Cells: From bench-top to bedside","author":"Young","year":"2014"},{"issue":"2","key":"10.1016\/j.intimp.2024.112020_b1050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2329-6895.1000121","article-title":"Treating Parkinson disease with adult stem cells","volume":"1","author":"Young","year":"2013","journal-title":"J Neurol Disord"},{"key":"10.1016\/j.intimp.2024.112020_b1055","doi-asserted-by":"crossref","DOI":"10.4172\/2157-7633.C1.018","article-title":"Endogenous stem cells as a treatment for celiac disease, a case report","volume":"06","author":"Young","year":"2016","journal-title":"Journal of Stem Cell Research & Therapy"},{"issue":"1","key":"10.1016\/j.intimp.2024.112020_b1060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.52793\/JSCR.2023.4(1)-43","article-title":"Potential of stem cell based therapy to treat celiac disease and its complications","volume":"4","author":"Solanki","year":"2022","journal-title":"J Stem Cell Res"},{"key":"10.1016\/j.intimp.2024.112020_b1065","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2023.08.006","article-title":"Engineered hematopoietic and immune cells derived from human pluripotent stem cells","author":"Chang","year":"2023","journal-title":"Exp. Hematol."},{"issue":"15","key":"10.1016\/j.intimp.2024.112020_b1070","doi-asserted-by":"crossref","DOI":"10.1242\/dev.170571","article-title":"Hematopoietic stem cell-independent hematopoiesis and the origins of innate-like B lymphocytes","volume":"146","author":"Ghosn","year":"2019","journal-title":"Development"},{"issue":"6","key":"10.1016\/j.intimp.2024.112020_b1075","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/MOT.0000000000000586","article-title":"Mesenchymal stromal cell therapy in intestinal diseases","volume":"23","author":"Ciccocioppo","year":"2018","journal-title":"Curr. Opin. Organ Transplant."},{"issue":"4","key":"10.1016\/j.intimp.2024.112020_b1080","first-page":"239","article-title":"What is the best histopathological classification for celiac disease? Does it matter?","volume":"8","author":"Pe\u00f1a","year":"2015","journal-title":"Gastroenterol Hepatol Bed Bench"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924005381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924005381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T16:05:43Z","timestamp":1715616343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924005381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":216,"alternative-id":["S1567576924005381"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112020","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential therapeutic options for celiac Disease: An update on Current evidence from Gluten-Free diet to cell therapy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112020"}}